Cancer of the Cervix
Conditions
Keywords
Cervical Cancer, Cetuximab, Phase II Clinical Trials, Stage IB2-IVB Carcinoma of the Cervix
Brief summary
The anti-tumor activity of cetuximab prior to chemoradiotherapy and the safety and tolerability of cetuximab with concurrent chemoradiation will be determined in women with locally advanced or metastatic cervical carcinoma.
Detailed description
* Women with Federation of Gynecology and Obstetrics (FIGO) Clinical Stage IB2-IVB carcinoma of the cervix * Baseline cervical biopsy, blood samples, and FDG-PET/computed tomography (CT) scan * Cetuximab 400 mg/m2 on day 1 followed by cetuximab 250 mg/m2 on days 8 and 15 * Repeat cervical biopsy and FDG-PET/CT scan following cetuximab monotherapy * Radiation and weekly cisplatin 40 mg/m2 and cetuximab 250 mg/2 for 6 weeks * Cetuximab 250 mg/m2 weekly for 12 weeks * Repeat cervical biopsy (if tumor present) and FDG-PET/CT scan after completion of therapy * Follow for tumor recurrence and survival
Interventions
DRUGCetuximab
monotherapy (day 1), then weekly thereafter along with radiation. dose is at 200mg/m2.
Sponsors
Bristol-Myers Squibb
Eli Lilly and Company
Washington University School of Medicine
University of Virginia
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients must have signed a Washington University, Human Studies Committee (HSC) approved, informed consent. 2. Patients must have primary, histologically documented FIGO Clinical Stage IB2-IVB invasive carcinoma of the uterine cervix with measurable disease amendable to repeated biopsy. 3. Patients must have an ECOG performance status of 0, 1, or 2 at study entry. 4. Patients, 18 years and older, must either be not of child bearing potential or have a negative pregnancy test within 7 days of treatment. Patients are considered not of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal. Women should not breast feed while on this study. 5. Women must have a primary diagnosis of invasive carcinoma of the uterine cervix. Men are excluded from this study as a consequence of the diagnosis being investigated. 6. Patients must have had no previous treatment for invasive carcinoma of the uterine cervix. 7. Patients must be newly diagnosed with locally advanced or metastatic cervical carcinoma. 8. Bone marrow function: absolute neutrophil count (ANC) ≥ 1,500/mcl; platelets \> 100,000/mcl. 9. Renal function: creatinine ≤ 2.0 mg/dl. 10. Hepatic function: bilirubin ≤ 1.5 times upper limit normal (ULN); SGOT ≤ 2.5 times upper limit normal (ULN). 11. Patients with ureteral obstruction must be treated with stent or nephrostomy tube placement. 12. Patients with neuropathy (sensory and motor) must be ≤ grade 1 defined by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 (June 10, 2003).
Exclusion criteria
1. Acute hepatitis or known HIV. 2. Active or uncontrolled infection. 3. Significant history of uncontrolled cardiac disease i.e., uncontrolled hypertension, unstable angina, recent myocardial infarction (within prior 6 months), uncontrolled congestive heart failure, and cardiomyopathy with decreased ejection fraction. 4. Prior therapy which specifically and directly targets the EGFR pathway. 5. Prior severe infusion reaction to a monoclonal antibody. 6. Any concurrent chemotherapy not indicated in the study protocol or any other investigational agent(s). 7. A serious uncontrolled medical disorder that in the opinion of the Investigator would impair the ability of the subject to receive protocol therapy. 8. Unresolved ureteral obstruction. 9. Renal abnormalities, such as pelvic kidney, horseshoe kidney, or renal transplant, that would require modification of radiation fields. 10. Known or documented brain metastases. 11. Any concurrent malignancy other than non-melanoma skin cancer. (Patients with a previous malignancy but without evidence of disease for ≥ 5 years will be allowed to enter the trial). 12. Prior radiation therapy to the abdomen and/or pelvis 13. Incarceration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To identify genes that may be identified as predictive of response to cetuximab | completion |
| To sequence the epidermal growth factor receptor (EGFR) to describe mutations in the receptor that may predict tumor response to cetuximab | completion |
| To evaluate the validity of fluorodeoxyglucose (FDG) uptake, as determined by positron emission tomography (PET) imaging, as a surrogate marker for response to cetuximab | completion |
Secondary
| Measure | Time frame |
|---|---|
| To determine the safety and tolerability of cetuximab with concurrent chemoradiation in women with locally advanced cervical carcinoma | weekly |
| To determine the progression-free and overall survival in women with locally advanced or metastatic cervical carcinoma treated with concurrent chemoradiation and cetuximab | every three months |
Countries
United States
Contacts
Primary ContactMeredith Gross, M.S.
Outcome results
None listed